A thorough QT study to evaluate the effects of single-dose exenatide 10 μg on cardiac repolarization in healthy subjects

International Journal of Clinical Pharmacology and Therapeutics

Volumn 49, Issue 10, 2011, Pages 594-605

  Linnebjerg, H ^a   Seger, M ^a   Kothare, P A ^a   Hunt, T ^a   Wolka, A M ^a   Mitchell, M I ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Exenatide; ICH E14; Moxifloxacin; QTc; Thorough QT

Indexed keywords

EXENDIN 4; GLUCOSE; INSULIN; MOXIFLOXACIN; PLACEBO;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR SYSTEM EXAMINATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG FATALITY; ELECTROCARDIOGRAM; FEMALE; FRIDERICIA QT CORRECTION; GLUCOSE BLOOD LEVEL; HEADACHE; HEART RATE; HEART REPOLARIZATION; HUMAN; HUMAN EXPERIMENT; HYPOGLYCEMIA; INDIVIDUAL QT CORRECTION; INSULIN BLOOD LEVEL; INSULIN RELEASE; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NAUSEA; NORMAL HUMAN; PULSE RATE; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; VOMITING;

ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PEPTIDES; RECEPTORS, GLUCAGON; VENOMS;

EID: 80053606722     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201462     Document Type: Article

References (25)

1. Stonehouse A, Okerson T, Kendall D, Maggs D. Emerging incretin based therapies for type 2 diabetes: incretin mimetics and DPP-4 inhibitors. Curr Diabetes Rev. 2008; 4: 101-109. doi: 10.2174/157339908784220705 PubMed
2. Byetta prescribing information. http://pi.lilly.com/us/byetta-pi.pdf. Accessed 04 February 2011.
3. Kothare PA, Linnebjerg H, Isaka Y, Uenaka K, Yamamura A, Yeo KP, De la Peña A, Teng CH, Mace K, Fineman M, Shigeta H, Sakata Y, Irie S. Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus. J Clin Pharmacol. 2008; 48: 1389-1399. doi: 10.1177/0091270008323750 PubMed
4. Kothare PA, Linnebjerg H, Skrivanek Z, Reddy S, Mace K, Pena A, Han J, Fineman M, Mitchell M. Exenatide effects on statin pharmacokinetics and lipid response. Int J Clin Pharmacol Ther. 2007; 45: 114-120. PubMed (Pubitemid 46344143)
5. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs: E14. 2005. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ ucm129357.pdf. Accessed 04 February 2011.
6. Blase E, Taylor K, Gao HY, Wintle M, Fineman M. Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects. J Clin Pharmacol. 2005; 45: 570-577. doi: 10.1177/0091270004274432 PubMed (Pubitemid 40562948)
7. Kothare PA, Soon DK, Linnebjerg H, Park S, Chan C, Yeo A, Lim M, Mace KF, Wise SD. Effect of exenatide on the steady-state pharmacokinetics of digoxin. J Clin Pharmacol. 2005; 45: 1032-1037. doi: 10.1177/0091270005278806 PubMed (Pubitemid 41192362)
8. Soon D, Kothare PA, Linnebjerg H, Park S, Yuen E, Mace KF, Wise SD. Effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy Asian men. J Clin Pharmacol. 2006; 46: 1179-1187. doi: 10.1177/0091270006291622 PubMed (Pubitemid 44387418)
9. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005; 28: 1092-1100. doi: 10.2337/diacare.28.5.1092 PubMed (Pubitemid 40616618)
10. Fineman MS, Shen LZ, Taylor K, Kim DD, Baron AD. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab Res Rev. 2004; 20: 411-417. doi: 10.1002/dmrr.499 PubMed (Pubitemid 39302967)
11. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005; 28: 1083-1091. doi:10.2337/diacare.28.5.1083 PubMed (Pubitemid 40616617)
12. Fridericia LS. The duration of systole in an electrocardiogram in normal humans and in patients with heart disease. 1920. Ann Noninvasive Electrocardiol. 2003; 8: 343-351. doi: 10.1046/j.1542-474X.2003.08413.x PubMed (Pubitemid 38569971)
13. Marques JL, George E, Peacey SR, Harris ND, Macdonald IA, Cochrane T, Heller SR. Altered ventricular repolarization during hypoglycaemia in patients with diabetes. Diabet Med. 1997; 14: 648-654. doi: 10.1002/(SICI)1096- 9136(199708)14:8〈648::AID-DIA418〉3.0.CO:2-1 PubMed (Pubitemid 27346853)
14. Eckert B, Agardh CD. Hypoglycaemia leads to an increased QT interval in normal men. Clin Physiol. 1998; 18: 570-575. doi: 10.1046/j.1365-2281.1998. 00138.x PubMed (Pubitemid 28488455)
15. Marfella R, Nappo F, De Angelis L, Siniscalchi M, Rossi F, Giugliano D. The effect of acute hyperglycaemia on QTc duration in healthy man. Daibetologia. 2000; 43: 571-575. doi: 10.1007/s001250051345 PubMed (Pubitemid 30322074)
16. Landstedt-Hallin L, Englund A, Adamson U, Lins PE. Increased QT dispersion during hypoglycaemia in patients with type 2 diabetes mellitus. J Intern Med. 1999; 246: 299-307. doi: 10.1046/j.1365-2796.1999.00528.x PubMed (Pubitemid 29426449)
17. Gastaldelli A, Emdin M, Conforti F, Camastra S, Ferrannini B. Insulin prolongs the QTc interval in humans. Am J Physiol Regul Integr Comp Physiol. 2000; 279: 2022-2025. PubMed
18. Bazett HC. An analysis of time-relations of electrocardiograms. Heart. 1920; 7: 353-370.
19. Zhang L, Dmitrienko A, Luta G. Sample size calculations in thorough QT studies. J Biopharm Stat. 2008; 18: 468-482. doi: 10.1080/10543400801993002 PubMed (Pubitemid 351891686)
20. Bloomfield DM, Kost JT, Ghosh K, Hreniuk D, Hickey LA, Guitierrez MJ, Gottesdiener K, Wagner JA. The effect of moxifloxacin on QTc and implications for the design of thorough QT studies. Clin Pharmacol Ther. 2008; 84: 475-480. doi: 10.1038/clpt.2008.33 PubMed
21. Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A, Kim D, Baron AD. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metfonnin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care. 2003; 26: 2370-2377. doi: 10.2337/diacare.26.8.2370 PubMed (Pubitemid 36993328)
22. Westfall PH, Tobias RD, Rom D, Wolfinger RD, Hochberg Y. Multiple comparisons and multiple tests using SAS. Cary, NC, USA: SAS Press; 1999.
23. Garnett CE, Beasley N, Bhattaram VA, Jadhav PR, Madabushi R, Stockbridge N, Tornøe CW, Wang Y, Zhu H, Gobburu JV. Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review. J Clin Pharmacol. 2008; 48: 13-18. doi: 10.1177/0091270007307881 PubMed (Pubitemid 350292272)
24. Avelox prescribing information. http://www.avelox.com/html/pdf/avelox- prescribing.pdf. Accessed 04 February 2011.
25. Tornøe CW, Garnett CE, Wang Y, Florian J, Li M, Gobburu J. V. Creation of a knowledge management system for QT analyses. J Clin Pharmacol. 2011; 51: 1035-1042. Epub 2010 Oct 26. PubMed